Payment overview · 2025
General Payments
$2,078.43
58 reported records · 16 companies
Healthcare provider profile · identity verified
Paula C Henderson, MD
Allopathic & Osteopathic Physicians|Family Medicine · HEMET, CA · NPI 1275646317
Verified facts
What the public records show
CMS Open Payments records show Paula C Henderson, MD received $2,078.43 in general payments during 2025 across 58 reported records.
Amgen Inc. accounted for 40.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Prolia, Rybelsus, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $831.55 | 40.0% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $289.52 | 13.9% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $186.04 | 8.9% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $140.48 | 6.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $119.25 | 5.7% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $98.09 | 4.7% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $97.22 | 4.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $63.95 | 3.1% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $56.70 | 2.7% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $40.51 | 1.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $38.81 | 1.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.13 | 1.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $27.95 | 1.3% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $23.47 | 1.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.23 | 0.9% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $15.53 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,078.43 | 58 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $706.81 | 18 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $251.51 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $213.67 | 14 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $186.04 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $140.48 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $119.25 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $98.09 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $97.21 | 6 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $80.26 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $38.81 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $38.01 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $30.13 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.71 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $27.95 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $27.95 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.11 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.11 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $9.53 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $9.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 64 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 187 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 27 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 73 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 86 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
27 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
86 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
64 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
187 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
73 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 700 | 229 |
| Atorvastatin Calcium | Atorvastatin Calcium | 625 | 220 |
| Allopurinol | Allopurinol | 624 | 219 |
| Levothyroxine Sodium | Levothyroxine Sodium | 609 | 175 |
| Losartan Potassium | Losartan Potassium | 537 | 194 |
| Metformin Hcl | Metformin Hcl | 451 | 155 |
| Lisinopril | Lisinopril | 446 | 142 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 438 | 99 |
| Fenofibrate | Fenofibrate | 430 | 150 |
| Omeprazole | Omeprazole | 360 | 129 |
| Hydrochlorothiazide | Hydrochlorothiazide | 292 | 107 |
| Gabapentin | Gabapentin | 257 | 94 |
| Trazodone Hcl | Trazodone Hcl | 215 | 58 |
| Furosemide | Furosemide | 199 | 68 |
| Atenolol | Atenolol | 190 | 59 |
| Ozempic | Semaglutide | 187 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 184 | 62 |
| Repatha Sureclick | Evolocumab | 175 | 38 |
| Glipizide | Glipizide | 163 | 68 |
| Gemfibrozil | Gemfibrozil | 153 | 63 |
| Simvastatin | Simvastatin | 153 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 149 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 147 | 58 |
| Famotidine | Famotidine | 145 | 52 |
| Paroxetine Hcl | Paroxetine Hcl | 144 | 52 |
| Eliquis | Apixaban | 140 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 139 | 33 |
| Januvia | Sitagliptin Phosphate | 131 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 131 | 53 |
| Myrbetriq | Mirabegron | 126 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 123 | 44 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 118 | 17 |
| Tramadol Hcl | Tramadol Hcl | 118 | 46 |
| Azithromycin | Azithromycin | 117 | 92 |
| Clopidogrel | Clopidogrel Bisulfate | 114 | 41 |
| Temazepam | Temazepam | 112 | 20 |
| Clonidine Hcl | Clonidine Hcl | 99 | 38 |
| Carvedilol | Carvedilol | 93 | 36 |
| Benazepril Hcl | Benazepril Hcl | 91 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 91 | 12 |
| Alprazolam | Alprazolam | 90 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 87 | 33 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 86 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 86 | 31 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 84 | 32 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 83 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 25 |
| Rybelsus | Semaglutide | 73 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 24 |
| Ibuprofen | Ibuprofen | 68 | 25 |
| Clonidine | Clonidine | 66 | 17 |
| Mounjaro | Tirzepatide | 64 | 12 |
| Donepezil Hcl | Donepezil Hcl | 62 | 26 |
| Lorazepam | Lorazepam | 62 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 61 | 21 |
| Finasteride | Finasteride | 60 | 22 |
| Meloxicam | Meloxicam | 60 | 29 |
| Clonazepam | Clonazepam | 56 | 14 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 56 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 31 |
| Fluconazole | Fluconazole | 48 | 26 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 48 | 17 |
| Montelukast Sodium | Montelukast Sodium | 48 | 15 |
| Potassium Chloride | Potassium Chloride | 48 | 18 |
| Sertraline Hcl | Sertraline Hcl | 48 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 14 |
| Lovastatin | Lovastatin | 45 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 25 |
| Baclofen | Baclofen | 42 | 23 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 41 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Repatha Syringe | Evolocumab | 40 | 13 |
| Buspirone Hcl | Buspirone Hcl | 39 | 15 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Flunisolide | Flunisolide | 38 | 22 |
| Alendronate Sodium | Alendronate Sodium | 36 | 14 |
| Nitroglycerin | Nitroglycerin | 35 | 22 |
| Meclizine Hcl | Meclizine Hcl | 34 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 12 |
| Lidocaine | Lidocaine | 33 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 29 |
| Trulicity | Dulaglutide | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Prolia | Denosumab | 27 | 17 |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 23 | suppressed |
| Lactulose | Lactulose | 23 | 12 |
| Megestrol Acetate | Megestrol Acetate | 23 | suppressed |
| Febuxostat | Febuxostat | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | 11 |
| Naproxen | Naproxen | 22 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Levofloxacin | Levofloxacin | 20 | suppressed |
| Nystatin | Nystatin | 20 | 11 |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | 13 |
| Cephalexin | Cephalexin | 19 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 13 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 13 | suppressed |
| Mycophenolic Acid | Mycophenolate Sodium | 13 | suppressed |
| Ssd | Silver Sulfadiazine | 13 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Alogliptin | Alogliptin Benzoate | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,078.43 · 58 records | Amgen Inc. | ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, CAPVAXIVE, EVENITY, FREESTYLE LIBRE 3, GARDASIL 9, INGREZZA, Korlym, LOREEV XR, MOUNJARO, OTEZLA, Ozempic, PROLIA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, VOQUEZNA, Wegovy, XIFAXAN, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error